MARKET

SAVA

SAVA

Cassava Sciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.240
-0.005
0.00%
Closed 16:00 11/15 EST
OPEN
1.220
PREV CLOSE
1.240
HIGH
1.240
LOW
1.205
VOLUME
92.41K
TURNOVER
--
52 WEEK HIGH
1.490
52 WEEK LOW
0.7600
MARKET CAP
21.35M
P/E (TTM)
-5.6159
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SAVA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SAVA News

  • We Think Cassava Sciences (NASDAQ:SAVA) Can Easily Afford To Drive Business Growth
  • Simply Wall St..11/05 17:06
  • Cassava Sciences EPS beats by $0.07
  • seekingalpha.10/29 17:21
  • Cassava Sciences Q3 EPS $(0.04) Up From $(0.11) YoY
  • Benzinga.10/29 12:18
  • Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results
  • GlobeNewswire.10/29 12:15

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About SAVA

Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing drug for the treatment of nervous system disorders. The Company is ocused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Its drug candidate, PTI-125, is a small molecule that targets an altered form of a scaffolding protein called filamin A (FLNA). The Company is also developing an experimental biomarker/diagnostic, PTI-125Dx. It is developing PTI-125Dx to detect Alzheimer’s disease with a blood test.
More

Webull offers Cassava Sciences Inc (SAVA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.